• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种解决奥卡姆剃刀问题的贝叶斯区间剂量探索设计:mTPI-2。

A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.

作者信息

Guo Wentian, Wang Sue-Jane, Yang Shengjie, Lynn Henry, Ji Yuan

机构信息

School of Public Health, Fudan University, PR China.

Office of Biostatistics/Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, United States.

出版信息

Contemp Clin Trials. 2017 Jul;58:23-33. doi: 10.1016/j.cct.2017.04.006. Epub 2017 Apr 27.

DOI:10.1016/j.cct.2017.04.006
PMID:28458054
Abstract

There has been an increasing interest in using interval-based Bayesian designs for dose finding, one of which is the modified toxicity probability interval (mTPI) method. We show that the decision rules in mTPI correspond to an optimal rule under a formal Bayesian decision theoretic framework. However, the probability models in mTPI are overly sharpened by the Ockham's razor, which, while in general helps with parsimonious statistical inference, leads to undesirable decisions from safety perspective. We propose a new framework that blunts the Ockham's razor, and demonstrate the superior performance of the new method, called mTPI-2. An online web tool is provided for users who can generate the design, conduct clinical trials, and examine operating characteristics of the designs.

摘要

人们对使用基于区间的贝叶斯设计进行剂量探索的兴趣与日俱增,其中一种方法是改良毒性概率区间(mTPI)法。我们表明,mTPI中的决策规则对应于形式贝叶斯决策理论框架下的最优规则。然而,mTPI中的概率模型因奥卡姆剃刀原则而过度简化,虽然这通常有助于进行简洁的统计推断,但从安全性角度来看会导致不良决策。我们提出了一个弱化奥卡姆剃刀原则的新框架,并展示了名为mTPI-2的新方法的卓越性能。为用户提供了一个在线网络工具,用户可以生成设计、进行临床试验并检查设计的操作特征。

相似文献

1
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.一种解决奥卡姆剃刀问题的贝叶斯区间剂量探索设计:mTPI-2。
Contemp Clin Trials. 2017 Jul;58:23-33. doi: 10.1016/j.cct.2017.04.006. Epub 2017 Apr 27.
2
A modified toxicity probability interval method for dose-finding trials.改良毒性概率区间法在探索性剂量试验中的应用。
Clin Trials. 2010 Dec;7(6):653-63. doi: 10.1177/1740774510382799. Epub 2010 Oct 8.
3
Performance of toxicity probability interval based designs in contrast to the continual reassessment method.基于毒性概率区间的设计与连续重新评估方法的性能对比。
Stat Med. 2017 Jan 30;36(2):291-300. doi: 10.1002/sim.7043. Epub 2016 Jul 19.
4
Comparative review of novel model-assisted designs for phase I clinical trials.新型模型辅助设计在 I 期临床试验中的比较综述。
Stat Med. 2018 Jun 30;37(14):2208-2222. doi: 10.1002/sim.7674. Epub 2018 Apr 22.
5
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.斯坦因:用于无缝I/II期临床试验的简单毒性和疗效区间设计。
Stat Med. 2017 Nov 20;36(26):4106-4120. doi: 10.1002/sim.7428. Epub 2017 Aug 7.
6
Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.《键盘:一种用于I期临床试验的新型贝叶斯毒性概率区间设计》
Clin Cancer Res. 2017 Aug 1;23(15):3994-4003. doi: 10.1158/1078-0432.CCR-17-0220. Epub 2017 May 25.
7
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.贝叶斯最优区间设计:一种用于I期肿瘤试验的简单且性能良好的设计。
Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.
8
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.改良毒性概率区间设计:比 3+3 设计更安全、更可靠的实用 I 期临床试验方法。
J Clin Oncol. 2013 May 10;31(14):1785-91. doi: 10.1200/JCO.2012.45.7903. Epub 2013 Apr 8.
9
A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.基于缩小预测概率的两药联合Ⅰ期临床试验剂量探索方法。
Stat Med. 2013 Nov 20;32(26):4515-25. doi: 10.1002/sim.5843. Epub 2013 May 6.
10
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.新型 I 期临床试验设计的准确性、安全性和可靠性。
Clin Cancer Res. 2018 Sep 15;24(18):4357-4364. doi: 10.1158/1078-0432.CCR-18-0168. Epub 2018 Apr 16.

引用本文的文献

1
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.一项关于间歇性他拉唑帕利联合替莫唑胺治疗转移性去势抵抗性前列腺癌且DNA损伤反应基因无突变患者的1b/2期研究。
Invest New Drugs. 2025 Sep 4. doi: 10.1007/s10637-025-01580-1.
2
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors.STING激动剂E7766在晚期实体瘤中的I期剂量递增及药效学研究。
J Immunother Cancer. 2025 Feb 20;13(2):e010511. doi: 10.1136/jitc-2024-010511.
3
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.
B细胞成熟抗原(BCMA)NEX-T®嵌合抗原受体(CAR)T细胞疗法CC-98633/BMS-986354用于三重暴露的多发性骨髓瘤患者的1期临床试验。
Leukemia. 2025 Apr;39(4):816-826. doi: 10.1038/s41375-025-02518-5. Epub 2025 Feb 5.
4
MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials.MT键盘:一种用于I期试验中考虑毒性等级和类型的贝叶斯模型辅助区间设计。
Stat Biopharm Res. 2024;16(3):305-314. doi: 10.1080/19466315.2024.2368802. Epub 2024 Jul 31.
5
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.在初治的成年B-ALL患者中开展的携带全人源单链抗体片段(scFv)的CD19嵌合抗原受体(CAR)T细胞疗法的1期研究。
Blood Adv. 2025 Apr 22;9(8):1861-1872. doi: 10.1182/bloodadvances.2024015314.
6
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.在晚期肿瘤患者中靶向 PD-1 和 PD-L1 的首创双特异性抗体 IBI318(LY3434172):一项 Ia/Ib 期研究。
J Hematol Oncol. 2024 Nov 29;17(1):118. doi: 10.1186/s13045-024-01644-4.
7
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.一项在晚期实体瘤患者中进行的系统联合使用 MEDI5395(NDV-GM-CSF)重组减毒溶瘤病毒和度伐利尤单抗的 I 期研究。
J Immunother Cancer. 2024 Nov 17;12(11):e009336. doi: 10.1136/jitc-2024-009336.
8
Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index.使用修正的脆弱性指数对肿瘤学剂量探索试验进行稳健性评估。
Cancers (Basel). 2024 Oct 17;16(20):3504. doi: 10.3390/cancers16203504.
9
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.一项评估 CD40 激动剂 MEDI5083 联合度伐利尤单抗治疗晚期实体瘤患者的 I 期临床研究。
Immunotherapy. 2024;16(11):759-774. doi: 10.1080/1750743X.2024.2359359. Epub 2024 Sep 12.
10
First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.KN046 联合化疗和姑息性放疗一线治疗晚期食管鳞癌的开放标签、剂量递增和扩展的 Ib 期临床试验。
Cancer Immunol Immunother. 2024 Aug 6;73(10):194. doi: 10.1007/s00262-024-03769-4.